Infusions of interleukin-1α after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity

Emmanuel Katsanis, Daniel J. Weisdorf, Zhiyi Xu, Betsy B. Dancisak, Mary L. Halet, Bruce R. Blazar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We evaluated the cytolytic function, phenotypic characteristics, and cytokine levels of 22 patients with non-Hodgkin's lymphoma and 7 with Hodgkin's disease receiving interleukin-la (IL-1α) following autologous bone marrow or peripheral blood stem cell transplantation. IL-1α was given i.v. over 6 hr, between day 0 and day +13 posttransplant. On day +14, cells from patients receiving high-dose IL-1α (3.0 μg/m2/day) had significantly enhanced killing of natural killer (NK)-sensitive and -resistant lymphoma targets compared to those treated with low-dose IL-1α (0.1, 0.3, or 1.0 μg/m2/day). The differences in cytolytic function between the two groups persisted but were not as striking on day +28. Patients receiving higher-dose IL-1α had a significantly increased proportion of CD3+ T cells on days +14 and +28, while the proportion of CD16+ and CD56+ NK cells was decreased compared to those of patients treated with the lower dose. There were no detectable levels of IL-2, interferon-γ, or tumor necrosis factor-α in the plasma of patients receiving IL-1α posttransplant. However, higher-dose IL-1α therapy was associated with significant increases in serum IL-6 levels in comparison to those in patients receiving low-dose IL-1α. IL-1α may increase cytolytic function post-bone marrow transplantation; it remains to be determined, however, whether this would have an impact on decreasing relapse rates of patients undergoing transplantation for lymphoma.

Original languageEnglish (US)
Pages (from-to)205-211
Number of pages7
JournalJournal of Clinical Immunology
Volume14
Issue number3
DOIs
StatePublished - May 1994
Externally publishedYes

Fingerprint

Autologous Transplantation
Hodgkin Disease
Interleukin-1
Non-Hodgkin's Lymphoma
Lymphoma
Peripheral Blood Stem Cell Transplantation
Interleukins
Bone Marrow Transplantation
Natural Killer Cells
Interferons
Interleukin-2
Interleukin-6
Tumor Necrosis Factor-alpha
Transplantation
Bone Marrow
Cytokines
T-Lymphocytes
Recurrence

Keywords

  • bone marrow transplantation
  • IL-6
  • Interleukin-1 (IL-1)
  • lymphoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Infusions of interleukin-1α after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity. / Katsanis, Emmanuel; Weisdorf, Daniel J.; Xu, Zhiyi; Dancisak, Betsy B.; Halet, Mary L.; Blazar, Bruce R.

In: Journal of Clinical Immunology, Vol. 14, No. 3, 05.1994, p. 205-211.

Research output: Contribution to journalArticle

@article{54e212c8c469427cb2e050e6cfb53e4d,
title = "Infusions of interleukin-1α after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity",
abstract = "We evaluated the cytolytic function, phenotypic characteristics, and cytokine levels of 22 patients with non-Hodgkin's lymphoma and 7 with Hodgkin's disease receiving interleukin-la (IL-1α) following autologous bone marrow or peripheral blood stem cell transplantation. IL-1α was given i.v. over 6 hr, between day 0 and day +13 posttransplant. On day +14, cells from patients receiving high-dose IL-1α (3.0 μg/m2/day) had significantly enhanced killing of natural killer (NK)-sensitive and -resistant lymphoma targets compared to those treated with low-dose IL-1α (0.1, 0.3, or 1.0 μg/m2/day). The differences in cytolytic function between the two groups persisted but were not as striking on day +28. Patients receiving higher-dose IL-1α had a significantly increased proportion of CD3+ T cells on days +14 and +28, while the proportion of CD16+ and CD56+ NK cells was decreased compared to those of patients treated with the lower dose. There were no detectable levels of IL-2, interferon-γ, or tumor necrosis factor-α in the plasma of patients receiving IL-1α posttransplant. However, higher-dose IL-1α therapy was associated with significant increases in serum IL-6 levels in comparison to those in patients receiving low-dose IL-1α. IL-1α may increase cytolytic function post-bone marrow transplantation; it remains to be determined, however, whether this would have an impact on decreasing relapse rates of patients undergoing transplantation for lymphoma.",
keywords = "bone marrow transplantation, IL-6, Interleukin-1 (IL-1), lymphoma",
author = "Emmanuel Katsanis and Weisdorf, {Daniel J.} and Zhiyi Xu and Dancisak, {Betsy B.} and Halet, {Mary L.} and Blazar, {Bruce R.}",
year = "1994",
month = "5",
doi = "10.1007/BF01533369",
language = "English (US)",
volume = "14",
pages = "205--211",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Infusions of interleukin-1α after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity

AU - Katsanis, Emmanuel

AU - Weisdorf, Daniel J.

AU - Xu, Zhiyi

AU - Dancisak, Betsy B.

AU - Halet, Mary L.

AU - Blazar, Bruce R.

PY - 1994/5

Y1 - 1994/5

N2 - We evaluated the cytolytic function, phenotypic characteristics, and cytokine levels of 22 patients with non-Hodgkin's lymphoma and 7 with Hodgkin's disease receiving interleukin-la (IL-1α) following autologous bone marrow or peripheral blood stem cell transplantation. IL-1α was given i.v. over 6 hr, between day 0 and day +13 posttransplant. On day +14, cells from patients receiving high-dose IL-1α (3.0 μg/m2/day) had significantly enhanced killing of natural killer (NK)-sensitive and -resistant lymphoma targets compared to those treated with low-dose IL-1α (0.1, 0.3, or 1.0 μg/m2/day). The differences in cytolytic function between the two groups persisted but were not as striking on day +28. Patients receiving higher-dose IL-1α had a significantly increased proportion of CD3+ T cells on days +14 and +28, while the proportion of CD16+ and CD56+ NK cells was decreased compared to those of patients treated with the lower dose. There were no detectable levels of IL-2, interferon-γ, or tumor necrosis factor-α in the plasma of patients receiving IL-1α posttransplant. However, higher-dose IL-1α therapy was associated with significant increases in serum IL-6 levels in comparison to those in patients receiving low-dose IL-1α. IL-1α may increase cytolytic function post-bone marrow transplantation; it remains to be determined, however, whether this would have an impact on decreasing relapse rates of patients undergoing transplantation for lymphoma.

AB - We evaluated the cytolytic function, phenotypic characteristics, and cytokine levels of 22 patients with non-Hodgkin's lymphoma and 7 with Hodgkin's disease receiving interleukin-la (IL-1α) following autologous bone marrow or peripheral blood stem cell transplantation. IL-1α was given i.v. over 6 hr, between day 0 and day +13 posttransplant. On day +14, cells from patients receiving high-dose IL-1α (3.0 μg/m2/day) had significantly enhanced killing of natural killer (NK)-sensitive and -resistant lymphoma targets compared to those treated with low-dose IL-1α (0.1, 0.3, or 1.0 μg/m2/day). The differences in cytolytic function between the two groups persisted but were not as striking on day +28. Patients receiving higher-dose IL-1α had a significantly increased proportion of CD3+ T cells on days +14 and +28, while the proportion of CD16+ and CD56+ NK cells was decreased compared to those of patients treated with the lower dose. There were no detectable levels of IL-2, interferon-γ, or tumor necrosis factor-α in the plasma of patients receiving IL-1α posttransplant. However, higher-dose IL-1α therapy was associated with significant increases in serum IL-6 levels in comparison to those in patients receiving low-dose IL-1α. IL-1α may increase cytolytic function post-bone marrow transplantation; it remains to be determined, however, whether this would have an impact on decreasing relapse rates of patients undergoing transplantation for lymphoma.

KW - bone marrow transplantation

KW - IL-6

KW - Interleukin-1 (IL-1)

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0028181318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028181318&partnerID=8YFLogxK

U2 - 10.1007/BF01533369

DO - 10.1007/BF01533369

M3 - Article

VL - 14

SP - 205

EP - 211

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 3

ER -